Top Anti Cancer Imported Medicine Drugs in India - Pharama Five

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Buy Gavreto (Pralsetinib) Medicine in India

Gavreto (Pralsetinib)

Medicine name : Gavreto

Generic name : Pralsetinib

Manufactured By : Blueprint Medicines Corp

Indications : MTC

Medicine Description : Gavreto is a RET inhibitor for RET fusion-positive NSCLC, thyroid cancer, and medullary thyroid cancer (MTC). It blocks abnormal RET proteins, slowing cancer growth. Taken orally, it provides a precision medicine approach. Side effects include high blood pressure, liver enzyme elevation, fatigue, and immune-related reactions. Regular blood pressure and liver function monitoring is needed.

Product Introduction

Gavreto (Pralsetinib) is a targeted anticancer medicine used to treat certain cancers with RET gene alterations. It is used for adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for certain patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). Pralsetinib works by blocking abnormal RET signaling that promotes cancer cell growth and survival, helping to slow tumor growth and disease progression.

Gavreto (Pralsetinib) should be taken exactly as prescribed by your doctor. It is usually taken on an empty stomach, and the recommended dose and treatment duration depend on your cancer type and response to treatment. Swallow the capsules whole with water and do not crush or chew them. Regular medical check-ups and laboratory tests may be required to monitor your blood counts, liver function, and overall response to treatment.

Common side effects of Gavreto (Pralsetinib) may include constipation, high blood pressure, fatigue, muscle or joint pain, diarrhea, dry mouth, swelling, and changes in blood cell counts. Pralsetinib may also cause serious lung, liver, or bleeding-related problems in some patients. Inform your doctor if any side effect becomes severe or persistent. Before starting treatment, tell your doctor about your medical history and all medicines, vitamins, herbal products, or dietary supplements you are taking.

Uses Of Gavreto (Pralsetinib)

Treatment of RET-Positive Lung and Thyroid Cancers

Benefits Of Gavreto

Gavreto (Pralsetinib) is used to treat certain cancers with RET gene alterations, including metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and certain advanced or metastatic RET-mutant medullary thyroid cancer (MTC). It works by blocking abnormal RET signaling that supports cancer cell growth and survival, helping to reduce the growth of cancer cells and slow the progression of RET-altered cancers.

Side Effects Of Gavreto (Pralsetinib)

Some side effects of Gavreto (Pralsetinib) may improve as your body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Gavreto (Pralsetinib)

  • Constipation
  • High blood pressure
  • Fatigue
  • Muscle or joint pain
  • Diarrhea
  • Dry mouth
  • Swelling
  • Decreased appetite
  • Low blood cell counts
  • Changes in liver function
How To Use Gavreto

Gavreto (Pralsetinib) should be taken exactly as prescribed by your doctor. It is usually taken on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Swallow the capsules whole with water and do not crush, chew, or open them. Take it regularly at the recommended dose and do not change or stop treatment without consulting your doctor.

How Gavreto (Pralsetinib) Works

Gavreto (Pralsetinib) is a targeted therapy that blocks abnormal RET (rearranged during transfection) signaling. Certain RET fusions or mutations can send signals that promote cancer cell growth and survival. By inhibiting RET activity, Pralsetinib helps slow the growth and spread of cancer cells and may help control RET-altered non-small cell lung cancer and medullary thyroid cancer.

Safety Advice

AlcoholCONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Gavreto (Pralsetinib).

PregnancyCONSULT YOUR DOCTOR

Gavreto (Pralsetinib) may harm an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant.

BreastfeedingCONSULT YOUR DOCTOR

Do not breastfeed during treatment with Gavreto (Pralsetinib) and for the recommended period after the final dose. Consult your doctor for guidance.

DrivingCONSULT YOUR DOCTOR

Gavreto (Pralsetinib) may cause fatigue, dizziness, or other effects that can affect alertness. Avoid driving if these symptoms occur.

KidneyCAUTION

Inform your doctor if you have kidney problems before starting Gavreto (Pralsetinib). Your doctor may recommend appropriate monitoring.

LiverCAUTION

Tell your doctor if you have liver problems. Liver function may be monitored during treatment with Gavreto (Pralsetinib).

Quick Tips
  • Take Gavreto (Pralsetinib) exactly as prescribed and on an empty stomach as directed by your doctor.
  • Attend regular blood tests and medical check-ups to monitor blood counts, liver function, blood pressure, and treatment response.
  • Report unusual bleeding, severe fatigue, yellowing of the skin or eyes, or other concerning symptoms promptly.
  • Contact your doctor immediately if you develop new or worsening cough, breathing difficulties, or chest discomfort.
  • Inform your doctor about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible drug interactions.
  • Read More About - Gavreto (Pralsetinib) from Pharma Five.
Faq

General Question

Gavreto Medicine (Pralsetinib) is a prescription drug used to treat non-small cell lung cancer (NSCLC) that is positive for an RET gene fusion and has spread to other parts of the body.

Gavreto Medicine works as a tyrosine kinase inhibitor (TKI), specifically targeting and blocking the RET protein in cancer cells, which helps to stop their growth and spread.

Doctors prescribe Gavreto Medicine for adults with RET fusion-positive NSCLC or other RET-altered cancers who have not responded to previous treatments or require an alternative targeted therapy.

Gavreto Medicine is taken orally in tablet form, usually once daily, with or without food.

Common side effects of Gavreto Medicine include fatigue, diarrhea, constipation, musculoskeletal pain, high blood pressure, and liver enzyme changes.

Yes, Gavreto Medicine may cause serious side effects, including liver problems, lung issues, heart problems, and severe bleeding. Seek immediate medical attention if severe symptoms arise.

Gavreto Medicine is typically taken as long as it remains effective and is well-tolerated, or until your doctor advises stopping the treatment.

It is advisable to avoid alcohol while taking Gavreto Medicine, as it may increase the risk of liver toxicity and other side effects.

No, Gavreto Medicine can harm an unborn baby. Women should use effective contraception during treatment and consult a doctor if pregnancy is suspected.

Yes, Gavreto Medicine may interact with other drugs, including certain antibiotics, antifungals, and other cancer treatments. Inform your doctor about all medications you are taking.

If you miss a dose of Gavreto Medicine, take it as soon as you remember, but skip it if the next dose is near. Do not take two doses at the same time to make up for the missed dose.

Yes, Gavreto Medicine can be taken with or without food, although taking it with food might help to reduce stomach upset.

Avoid grapefruit, monitor your blood pressure regularly, and have liver function tests as recommended by your doctor while taking Gavreto Medicine.

Store Gavreto Medicine at room temperature, away from moisture, heat, and light. Keep it out of reach of children.

Gavreto Medicine is available by prescription at pharmacies or through specialized drug providers. Consult your healthcare provider for the best source. Pharma Five assists in its procurement.